Cargando…

Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review

INTRODUCTION: Osimertinib is the treatment of choice for epidermal growth factor receptor (EGFR)-mutated advanced non–small-cell lung cancer (NSCLC). Because of its high price, many low-income countries, such as Syria, cannot provide osimertinib, which makes it difficult to choose the appropriate tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Alali, Mousa, Saifo, Maher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448734/
https://www.ncbi.nlm.nih.gov/pubmed/37637235
http://dx.doi.org/10.36401/JIPO-22-29